RegeneRx Publishes Regulatory Update on RGN-259
ROCKVILLE, Md., Jan. 12, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published an update regarding the regulatory progress of RGN-259 on the Company's website at www.regenerx.com.
SOURCE RegeneRx Biopharmaceuticals, Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=PH29101&Transmission_Id=202201120930PR_NEWS_USPR_____PH29101&DateId=20220112)
Share this article